Here we show that within the class of available inhibitors of PI3K/mTOR pathway, compounds that selectively block mTORC1/mTORC2, such as the combined PI3K/mTOR inhibitor NVP-BEZ235, efficiently target MYCN protein stability and cause in vivo regression of neuroblastoma, a MYCN-driven pediatric tumor. The gene discussed is MTOR; the disease is neoplasm.